(Q36929806)

17 August 2017

1 reference

title

Progress in the treatment of acute myeloid leukemia (English)

1 reference

17 August 2017

1 reference

4

Hagop M Kantarjian

1 reference

17 August 2017

1

Farhad Ravandi

1 reference

17 August 2017

Alan K Burnett

2

1 reference

PubMed ID

17786921

17 August 2017

Edward D Agura

series ordinal

3

1 reference

PubMed ID

17786921

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

110

1 reference

17 August 2017

1900-1910

1 reference

17 August 2017

9

1 reference

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Prognostically useful gene-expression profiles in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

New agents in acute myeloid leukemia and other myeloid disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Methylation profiling in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Progress and challenges in the therapy of adult acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Implications of NRAS mutations in AML: a study of 2502 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23000

7 January 2021

Identifiers

DOI

10.1002/CNCR.23000

1 reference

17 August 2017

1 reference

PubMed ID

17786921